首页|期刊导航|中国合理用药探索|抗逆转录病毒治疗对人类免疫缺陷病毒感染者体重和体脂变化的影响

抗逆转录病毒治疗对人类免疫缺陷病毒感染者体重和体脂变化的影响OA

Effects of Antiretroviral Therapy on Changes in Body Weight and Body Fat in People Living with Human Immunodeficiency Virus

中文摘要英文摘要

抗逆转录病毒治疗(ART)的广泛应用使人类免疫缺陷病毒(HIV)感染由一种致死性感染性疾病转变为需要长期规范治疗和持续管理的疾病.然而,治疗期间HIV感染者(PLWH)出现的过度或快速体重增加与胰岛素抵抗、2 型糖尿病等代谢异常及心血管疾病风险增加密切相关.本文通过综述ART相关体重增加的流行病学特征、ART后发生的体重增加或体脂分布变化的代谢机制、药物种类、体重/体脂变化的特点和管理策略,强调PLWH患者内脏脂肪积聚比体重更能预测心血管及代谢风险.针对当前尚无明确指南规范ART期间的体重管理,本文总结了可能的干预策略,包括早期监测、药物调整、生活方式干预及代谢药物的应用.随着PLWH中代谢性共病负担不断增加,体重、脂肪分布及代谢风险管理应成为其长期综合管理的重要组成部分.

The widespread use of antiretroviral therapy(ART)has transformed human immunodeficiency virus(HIV)infection from a fatal infectious disease into a chronic condition requiring long-term standardized treatment and continuous management.However,excessive or rapid weight gain observed in people living with HIV(PLWH)during treatment is closely associated with an increased risk of metabolic abnormalities such as insulin resistance and type 2 diabetes mellitus,as well as cardiovascular disease.This review summarizes the epidemiological characteristics of ART-associated weight gain,the metabolic mechanisms underlying weight gain and body fat distribution changes following ART initiation,the influence of different drug classes,and the patterns and management strategies of changes in body weight and body fat.It emphasizes that visceral adipose tissue accumulation in PLWH is a stronger predictor of cardiovascular and metabolic risks than overall body weight.Given the current absence of clear guideline recommendations for weight management during ART,this review summarizes potential intervention strategies,including early monitoring,regimen adjustment,lifestyle modification,and the use of metabolic agents.With the increasing burden of metabolic comorbidities in PLWH,management of body weight,fat distribution and metabolic risk should become an integral part of long-term comprehensive care for PLWH.

杨婕;陈兴琼;石艳娥;徐寒;李惠琴

云南省传染病医院,昆明 650000云南省传染病医院,昆明 650000默沙东(中国)投资有限公司全球医学事务部,上海 200030默沙东(中国)投资有限公司全球医学事务部,上海 200030云南省传染病医院,昆明 650000

医药卫生

人类免疫缺陷病毒感染者糖尿病心血管疾病抗逆转录病毒治疗体重增加

people living with human immunodeficiency virusdiabetes mellituscardiovascular diseasesantiretroviral therapyweight gain

《中国合理用药探索》 2026 (8)

13-21,9

本项目由默沙东(中国)投资有限公司资助.

10.3969/j.issn.2096-3327.2026.08.003

评论